SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Eric Fader who wrote (459)3/31/1999 2:12:00 AM
From: out_of_the_loop   of 5582
 
Eric:

Zicam sales are, if you believe the report, better than anticipated. GUMM has announced that they are entering the nicotine gum market, that they are starting clinical trials on Zicam for allergy symptom relief, and that they have spent considerable money to ramp up production of their gum products. Some of us believe that the company is doing well as a turnaround and Zicam is icing on the cake. Some of us bought for Zicam and think that the company turnaround (of the gum products) is icing on the cake. Either way, the cake is there.

I cannot predict how the market will respond to this news in the short term, but the long term (these days long term is anything from hours to weeks to months...) looks very bright.

I probably just proved your statment true. LOL.

Howard
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News